POLH and ovarian carcinoma: Based on our result that mutation of the major Polη O-GlcNAcylation residue T457 sensitizes cell to cisplatin exposure, it is reasonable to speculate that targeting Polη O-GlcNAcylation in ovarian cancer cells may have potential therapeutic benefits.